Bank Mandiri (BMRI), one of Indonesia’s leading financial institutions, delivered an exceptional performance in November 2025, reporting a substantial bank-only net profit of IDR 5.3 trillion. This impressive figure marks a robust 28% year-on-year (YoY) and 29% month-on-month (MoM) surge, signaling a powerful rebound and setting the highest monthly net profit record within the last 12 months. This resurgence was primarily fueled by a strategic provision expense reversal, normalizing operational expenditure growth, and sustained strength in non-interest income.

Record-Setting November Profit Drives 11M25 Performance

The remarkable November outcome propelled Bank Mandiri’s 11-month 2025 (11M25) bank-only net profit to IDR 44.1 trillion. While this reflects a 6% YoY decline from the previous year, it already accounts for 87% of the consolidated consensus estimate for 2025F, outperforming the 85% realization achieved for 2024 consolidated figures in the same period last year. The November profit surge acted as a powerful tailwind, positioning the bank favorably as it approaches the year-end.

• Provision Expense Reversal: A strategic move to optimize financial reserves.
• Normalized Opex Growth: Reflecting increased operational efficiency after a period of elevated spending.
• Strong Non-Interest Income: A testament to the bank’s diversified revenue streams and robust fee-based activities.

Credit Expansion vs. NIM Pressure: A Balancing Act

Accelerated Credit Growth Amidst Liquidity Influx

Bank Mandiri’s credit growth showed significant acceleration, jumping to a robust +13% YoY in November 2025. This compares favorably to +11% YoY in October 2025 and +11% YoY in August 2025, prior to government liquidity injections. Concurrently, liquidity conditions continued to ease, evidenced by Third Party Funds (DPK) growth accelerating to +16% YoY in November 2025, up from +15% YoY in October 2025 and +10% YoY in August 2025.

Navigating the NIM Squeeze

Despite the vigorous credit expansion, a nuanced asset mix dynamic emerged. A significant portion of the increased liquidity gravitated towards other ‘earnings assets’ rather than exclusively driving loan growth. Coupled with a DPK surge primarily propelled by Time Deposits, this led to a relatively lower average Net Interest Margin (NIM) of 4.44% for the October-November 2025 period, compared to 4.58% in 9M25. This pressure on margins was explicitly highlighted by BMRI management during their 3Q25 earnings call, underscoring it as a key challenge.

Operational Prudence and Strengthening Asset Quality

Bank Mandiri demonstrated solid operational discipline, with Pre-Provision Operating Profit (PPOP) expanding a healthy +10% YoY in November 2025. This performance sharply contrasts with the -9% YoY recorded for 11M25, indicating a strong turn-around. The improvement was driven by consistently strong non-interest income growth, which soared to +24% YoY in November 2025 (vs. +12% YoY for 11M25), alongside a notable normalization in operating expense (Opex) growth to +9% YoY (vs. +37% YoY for 11M25). This Opex normalization aligns perfectly with management’s guidance, which anticipates relatively flat Opex in 2026F after a substantial increase in 2025.

Furthermore, Bank Mandiri registered a positive provision expense reversal of IDR 540 billion in November 2025, equating to a -0.5% Cost of Credit (CoC). This strategic move reinforces a clear downward trend in CoC over the past four months, starting from August 2025, signaling an improvement in asset quality and a more stable credit outlook.

Outlook: Navigating Future Growth with Strategic Agility

Bank Mandiri’s November 2025 performance underscores its resilience and strategic agility in a dynamic financial landscape. The robust profit recovery, driven by operational efficiencies and prudent financial management, paints a positive picture for its short-term trajectory. While NIM pressures present an ongoing challenge, the bank’s accelerated credit growth and improving asset quality indicate a strong foundation for sustainable future growth. Investors will keenly watch how BMRI continues to balance growth ambitions with margin optimization in the coming periods.